PATRYS Ltd (PAB) - Total Liabilities
Based on the latest financial reports, PATRYS Ltd (PAB) has total liabilities worth AU$1.01 Million AUD (≈ $711.96K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PATRYS Ltd (PAB) cash conversion ratio to assess how effectively this company generates cash.
PATRYS Ltd - Total Liabilities Trend (2007–2025)
This chart illustrates how PATRYS Ltd's total liabilities have evolved over time, based on quarterly financial data. Check PAB asset resilience ratio to evaluate the company's liquid asset resilience ratio.
PATRYS Ltd Competitors by Total Liabilities
The table below lists competitors of PATRYS Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Greenlane Holdings Inc
NASDAQ:GNLN
|
USA | $6.62 Million |
|
Silver Elephant Mining Corp
TO:ELEF
|
Canada | CA$33.58 Million |
|
Iceni Gold Ltd
AU:ICL
|
Australia | AU$1.11 Million |
|
Augros Cosmetic Packaging SA
PA:AUGR
|
France | €12.18 Million |
|
Perrot Duval Holding SA
SW:PEDU
|
Switzerland | CHF5.52 Million |
|
Khaitan (India) Limited
NSE:KHAITANLTD
|
India | Rs416.66 Million |
|
Kanger International Bhd
KLSE:0170
|
Malaysia | RM36.56 Million |
|
Biomind Labs Inc
NEO:BMND
|
Canada | CA$1.62 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down PATRYS Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PATRYS Ltd market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.74 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PATRYS Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PATRYS Ltd (2007–2025)
The table below shows the annual total liabilities of PATRYS Ltd from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$1.01 Million ≈ $711.96K |
+45.54% |
| 2024-06-30 | AU$691.37K ≈ $489.18K |
+0.65% |
| 2023-06-30 | AU$686.90K ≈ $486.02K |
+26.54% |
| 2022-06-30 | AU$542.83K ≈ $384.08K |
-36.13% |
| 2021-06-30 | AU$849.86K ≈ $601.33K |
+70.52% |
| 2020-06-30 | AU$498.38K ≈ $352.64K |
-21.81% |
| 2019-06-30 | AU$637.42K ≈ $451.02K |
-6.50% |
| 2018-06-30 | AU$681.77K ≈ $482.40K |
+37.58% |
| 2017-06-30 | AU$495.53K ≈ $350.62K |
-20.11% |
| 2016-06-30 | AU$620.26K ≈ $438.87K |
-22.69% |
| 2015-06-30 | AU$802.28K ≈ $567.67K |
-66.28% |
| 2014-06-30 | AU$2.38 Million ≈ $1.68 Million |
+120.06% |
| 2013-06-30 | AU$1.08 Million ≈ $765.05K |
+17.99% |
| 2012-06-30 | AU$916.36K ≈ $648.38K |
-33.63% |
| 2011-06-30 | AU$1.38 Million ≈ $976.96K |
+28.55% |
| 2010-06-30 | AU$1.07 Million ≈ $760.00K |
-26.41% |
| 2009-06-30 | AU$1.46 Million ≈ $1.03 Million |
+65.44% |
| 2008-06-30 | AU$882.30K ≈ $624.28K |
-62.55% |
| 2007-06-30 | AU$2.36 Million ≈ $1.67 Million |
-- |
About PATRYS Ltd
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated wit… Read more